TAIZHOU, Jiangsu Province, China, June 19 ShenzhenBeike Biotechnology Co., Ltd. ( http://www.beikebiotech.com ), a worldwideleader in providing safe and effective stem cell applications for medicaltreatment, has commenced outfitting its 21,500 square foot comprehensivemedical stem cell storage and processing facility in eastern China. When fullycompleted, the Jiangsu Stem Cell Storage Facility will be one of the mosthighly developed of its kind anywhere in the world, with advanced technologyand safe conditions to properly freeze, store, and process a broad range ofhuman stem cell samples for clinical application. The Stem Cell StorageFacility will initially provide stem cell banking for human umbilical cordblood stem cells, placenta stem cells, amniotic membrane stem cells, bonemarrow stem cells, and later will also be able to house induced pluripotentstem cells (iPS). Considered the future for stem cell treatments, iPS cellsare derived from cell reprogramming technologies and are a non-controversialpotential alternative to embryonic stem cells. Like umbilical cord blood stemcells, iPS cells can be preserved for later use in fighting a range ofdisorders.
Initially, the facility will be used primarily for private banking of stemcells by individuals, but as the number of samples increases, it will focus onpublic banking for medical facilities with the aim of allowing Beike to becomea global supplier for patients in need of stem cell transplants. Jiangsu BeikeBiotechnology Co., Ltd., a subsidiary of Shenzhen Beike Biotechnology Co.,Ltd., has been established to manage the facility.
Dr. Sean Hu, the Chairman of Beike Biotech said, "Stem cell storage is thenext logical step for us given our years of experience in handling andculturing stem cells to successfully treat patients from all over the world.With this groundbreaking new storage facility, Beike now leapfrogs to theforefront of the global stem cell industry by providing a large and securehome for the ammunition doctors need to fight debilitating disordersworldwide."
A new, technologically advanced laboratory will occupy ten thousand squarefeet of the Stem Cell Storage Facility and will produce quality Beike stemcells for use in treating patients in the leading hospitals of China's JiangsuProvince and greater Shanghai regions. Beike's stem cells are already usednationally in some of China's leading hospitals to treat more than 200patients per month suffering from a range of debilitating disorders likeAtaxia, Brain Injury, Cerebral Palsy, Diabetic Feet, Lower Limb Ischemia,Multiple Sclerosis, Muscular Dystrophy, Spinal Cord Injury and Optic NerveDamage. This new central processing laboratory model supersedes Beike's priorneed to build laboratories inside hospitals, meaning Beike treatments willbecome more affordable as stem cell component costs are reduced, fulfillingBeike's mission to improve the quality of life for as many patients aspossible.
The Stem Cell Storage Facility, which is set to be fully functional byyear end 2008, is located next to the 15,000 square foot Jiangsu BeikeBiotechnology office building, which already houses a showroom showcasingBeike's technologies and treatments. Beike ultimately plans for the entirefacility to be able to house up to 100,000 stem cell samples. To mark itsformal establishment, Beike hosted a grand opening ceremony at the site of thefacility which is located in Taizhou City within the prosperous easternprovince of Jiangsu. Jiangsu is rapidly becoming known as China's biotech andmedical capital, with Taizhou being touted by Chinese officials as "ChinaMedical City" (CMC). Several provincial and local officials were in attendanceat the ceremony including Mr. He Rong, The Assistant Mayor of Taizhou andDirector of the Taizhou New Medical Technology Industrial Park, among others.The Stem Cell Storage Facility and the Industrial Park where it is locate